Visiting Professors

ResearchToPractice.com/VPC109 - Case 2: A 77-year-old woman with a 9-cm, K-ras wild-type colon cancer and 42 out of 47 positive nodes who underwent resection of her primary tumor followed by adjuvant FOLFOX and subsequently developed a retroperitoneal metastasis treated with CAPOX/bevacizumab. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 3: A 57-year-old woman with T3N1 sigmoid colon cancer who received adjuvant FOLFOX. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 4: A 61-year-old woman with a 1.5-cm, K-ras mutation-positive, biopsy-proven metastasis to the lung 3.5 years after resection and chemoradiation therapy for rectal cancer. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 5: A 47-year-old woman with extrahepatic and hepatic metastases and lung nodules seven years after treatment for T3N0, K-ras wild-type colon cancer. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 6: A 63-year-old woman with T3N2M1, K-ras wild-type colon cancer underwent right colectomy and received CAPOX/bevacizumab for 10 months before discontinuing therapy and one year later underwent a pancreaticoduodenectomy for a tumor involving the duodenum, jejunum and pancreas. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 7: A 32-year-old mother of two children with a synchronous primary tumor and multiple sites of bilobar hepatic metastases (largest eight to nine centimeters). Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 8: A 53-year-old man with T3N1 rectal cancer eight to 10 centimeters from the anal verge received neoadjuvant capecitabine and radiation therapy followed by laparoscopic mesorectal excision and postoperative FOLFOX. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 9: A 57-year-old woman with poorly differentiated T3N0 adenocarcinoma of the sigmoid colon with minimal lymphovascular invasion received adjuvant FOLFOX. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 10: A 45-year-old woman with nearly obstructing, K-ras wild-type sigmoid colon cancer and diffuse, bilobar hepatic metastases who underwent one-step radiofrequency ablation of liver metastases and removal of the sigmoid colon. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 11: A 57-year-old man with T3N2, right-sided colon cancer, a large hemangioma and multiple hepatic metastases who was treated with FOLFOX/bevacizumab. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 12: A 61-year-old man with a 40-year history of interventions for rectal problems presented with T2 rectal cancer, refused colostomy and subsequently developed a small inguinal lymph node metastasis. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPC109 - Case 13: A 49-year-old man with inflammatory bowel disease presented with T3N1 rectal cancer and underwent complete mesorectal excision followed by adjuvant FOLFOX until CT revealed a hepatic lesion, at which point bevacizumab was added to the FOLFOX and the patient underwent resection of the hepatic lesion. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 1: A 45-year-old woman with a poorly differentiated papillary carcinoma of the lung with brain and adrenal metastases. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 2: A 53-year-old man with adenocarcinoma and metastatic disease to the skull who received radiation therapy followed by carboplatin/docetaxel/bevacizumab and maintenance bevacizumab. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 3: A 47-year-old woman with adenocarcinoma metastatic to the bone and axillary lymph nodes with a complete response to carboplatin/docetaxel/bevacizumab with zoledronic acid. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 4: A 54-year-old man with a highly symptomatic, Stage IIIB squamous cell carcinoma of the lung. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 5: A 66-year-old woman with a Stage IIIB adenocarcinoma of the lung treated with carboplatin/docetaxel/bevacizumab followed by maintenance pemetrexed/bevacizumab. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 6: A 68-year-old man with a Stage IIIB squamous cell carcinoma and significant pleural effusion. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 7: A 62-year-old woman who received adjuvant cisplatin/docetaxel after resection of a Stage IIIA adenocarcinoma of the lung. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/VPL109 – Case 8: A 55-year-old woman, a nonsmoker, who received single-agent erlotinib for bronchoalveolar carcinoma. Interviews conducted by Neil Love, MD. Produced by Research To Practice.